A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Berkeley, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Michelle Melisko
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Michelle Melisko
Dr. Michelle E. Melisko is a cancer specialist with expertise in breast cancer treatment and research. She is interested in testing new chemotherapy combinations, biological therapies and immunotherapies for breast cancer, with a particular focus on treatment of cancer that has spread to the brain.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
- ID
- NCT05514054
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 8000 study participants
- Last Updated